Molecule to Medicine

Molecule to Medicine (MTM): Building and Scaling Biotech Innovation

MTM invests in and builds high-impact biotech companies, leveraging our unique company creation model to drive transformative breakthroughs in drug discovery and development. We work alongside scientists, entrepreneurs, and investors to translate cutting-edge science into clinically successful therapeutics that address unmet needs of patients with serious diseases. Our Collective Intelligence approach ensures that we retain and develop top talent within our ecosystem, allowing us to continuously refine our company creation process—leveraging past learnings, shared expertise, and data-driven insights to efficiently launch and scale new biotech ventures.

Our Approach

We integrate deep scientific expertise, informatics-driven insights, and a highly efficient pod-based R&D model to de-risk and accelerate biotech ventures. Our track record includes:

• 5 investment-backed biotech companies launched
• $205M in venture capital raised
• $3M+ in non-dilutive funding secured
• Three global innovation hubs, including London and Oxford
• Faster and more capital efficient drug development compared with traditional models

How We Add Value

• Venture Creation & Investment – We co-create and fund high-potential biotech startups from inception through early-stage development with our expert team of drug developers and biotech operators.
• Integrated R&D Ecosystem – Our pod-based approach provides a capital-efficient, collaborative environment that de-risks and accelerates drug discovery programs through MTM’s agile infrastructure.
• Informatics & Data Science – We leverage an advanced informatics platform for target selection, indication prioritization, and clinical validation, improving decision-making and success rates.
• Scalable Business Model – We provide flexible, stage-appropriate teams that guide and support our companies from conception through to clinical execution, ensuring efficiency and long-term success.